Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:135295823" > A framework for rem...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04936naa a2200949 4500 | |
001 | oai:prod.swepub.kib.ki.se:135295823 | |
003 | SwePub | |
008 | 241002s2017 | |||||||||||000 ||eng| | |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1352958232 URI |
024 | 7 | a https://doi.org/10.1136/annrheumdis-2016-2095192 DOI |
040 | a (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a van Vollenhoven, Ru Karolinska Institutet4 aut |
245 | 1 0 | a A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS) |
264 | c 2016-11-24 | |
264 | 1 | b BMJ,c 2017 |
520 | a Treat-to-target recommendations have identified ‘remission’ as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.MethodsAn international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%.ResultsThe task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by …………………. (reference to symptoms, signs, routine labs).2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician's global assessment.3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics.The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life.ConclusionsThe work of this international task force provides a framework for testing different definitions of remission against long-term outcomes. | |
700 | 1 | a Voskuyl, A4 aut |
700 | 1 | a Bertsias, G4 aut |
700 | 1 | a Aranow, C4 aut |
700 | 1 | a Aringer, M4 aut |
700 | 1 | a Arnaud, L4 aut |
700 | 1 | a Askanase, A4 aut |
700 | 1 | a Balazova, P4 aut |
700 | 1 | a Bonfa, E4 aut |
700 | 1 | a Bootsma, H4 aut |
700 | 1 | a Boumpas, D4 aut |
700 | 1 | a Bruce, I4 aut |
700 | 1 | a Cervera, R4 aut |
700 | 1 | a Clarke, A4 aut |
700 | 1 | a Coney, C4 aut |
700 | 1 | a Costedoat-Chalumeau, N4 aut |
700 | 1 | a Czirjak, L4 aut |
700 | 1 | a Derksen, R4 aut |
700 | 1 | a Doria, A4 aut |
700 | 1 | a Dorner, T4 aut |
700 | 1 | a Fischer-Betz, R4 aut |
700 | 1 | a Fritsch-Stork, R4 aut |
700 | 1 | a Gordon, C4 aut |
700 | 1 | a Graninger, W4 aut |
700 | 1 | a Gyori, N4 aut |
700 | 1 | a Houssiau, F4 aut |
700 | 1 | a Isenberg, D4 aut |
700 | 1 | a Jacobsen, S4 aut |
700 | 1 | a Jayne, D4 aut |
700 | 1 | a Kuhn, A4 aut |
700 | 1 | a Le Guern, V4 aut |
700 | 1 | a Lerstrom, K4 aut |
700 | 1 | a Levy, R4 aut |
700 | 1 | a Machado-Ribeiro, F4 aut |
700 | 1 | a Mariette, X4 aut |
700 | 1 | a Missaykeh, J4 aut |
700 | 1 | a Morand, E4 aut |
700 | 1 | a Mosca, M4 aut |
700 | 1 | a Inanc, M4 aut |
700 | 1 | a Navarra, S4 aut |
700 | 1 | a Neumann, I4 aut |
700 | 1 | a Olesinska, M4 aut |
700 | 1 | a Petri, M4 aut |
700 | 1 | a Rahman, A4 aut |
700 | 1 | a Rekvig, OP4 aut |
700 | 1 | a Rovensky, J4 aut |
700 | 1 | a Shoenfeld, Y4 aut |
700 | 1 | a Smolen, J4 aut |
700 | 1 | a Tincani, A4 aut |
700 | 1 | a Urowitz, M4 aut |
700 | 1 | a van Leeuw, B4 aut |
700 | 1 | a Vasconcelos, C4 aut |
700 | 1 | a Voss, A4 aut |
700 | 1 | a Werth, VP4 aut |
700 | 1 | a Zakharova, H4 aut |
700 | 1 | a Zoma, A4 aut |
700 | 1 | a Schneider, M4 aut |
700 | 1 | a Ward, M4 aut |
710 | 2 | a Karolinska Institutet4 org |
773 | 0 | t Annals of the rheumatic diseasesd : BMJg 76:3, s. 554-561q 76:3<554-561x 1468-2060x 0003-4967 |
856 | 4 | u http://diposit.ub.edu/dspace/bitstream/2445/123199/1/678610.pdf |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:135295823 |
856 | 4 8 | u https://doi.org/10.1136/annrheumdis-2016-209519 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy